Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns
Breakthrough Innovation for the Purification of mRNA Therapeutics and Vaccines WALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of AVIPure ® dsRNA Clear OPUS ® columns, a groundbreaking solution designed to simplify and enhance the production of mRNA therapeutics and vaccines. This novel affinity chromatography offering marries Repligen’s breakthrough dsRNA purification resin with its flagship OPUS pre-packed columns. The AVIPure dsRNA Clear resin offers unmatched performance in the removal of double-stranded RNA (dsRNA) impurities from transcribed RNA. As the market for mRNA-based biologics has expanded, so has the critical need for better dsRNA removal, to enable the highest levels of drug efficacy in patients, while reducing or preventing any undesirable immune responses. The AVIPure dsRNA Clear OPUS columns directly address this need, with a